Arif Hakan Onder, Aysegul Seremet Keskin, Kubra Demir Onder, Filiz Kizilates, Cihan Heybeli
{"title":"癌症和非癌症患者因COVID-19住院期间发生急性缺血性事件的相关因素","authors":"Arif Hakan Onder, Aysegul Seremet Keskin, Kubra Demir Onder, Filiz Kizilates, Cihan Heybeli","doi":"10.5144/0256-4947.2023.1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 and solid cancer are both associated with an increased risk of thromboembolism.</p><p><strong>Objectives: </strong>Assess whether solid cancer is a risk factor for acute ischemic event development among patients with COVID-19.</p><p><strong>Design: </strong>Retrospective cohort SETTING: A tertiary training and research hospital PATIENTS AND METHODS: Patients who were hospitalized for COVID-19 for ≥3 days between 15 March 2020 and 30 March 2021 at Antalya Training and Research Hospital, Antalya, Turkiye. were included in the study. Independent predictors of the development of acute ischemic events during hospitalization were determined using multivariable logistic regression analysis.</p><p><strong>Main outcome measures: </strong>Risk factors for acute ischemic event development.</p><p><strong>Sample size: </strong>538 patients.</p><p><strong>Results: </strong>Patients diagnosed with solid cancer comprised 11.3% of the cohort (n=61). Forty-one (7.6%) developed an acute ischemic event at a median of 3 (range, 1-15) days after hospitalization. The presence of a solid cancer (OR 3.80, 95% CI 1.20-12.03, <i>P</i>=.023) along with length of hospital stay (OR 1.05 per day, 95% CI 1.01-1.09, <i>P</i>=.025) were independent predictors of acute ischemic event development during the course of COVID-19. Mortality was reported in 200 (37%) patients at a median of 5 (range, 3-10) days after hospitalization. The presence of solid tumor increased mortality 5.83 times (95% CI 3.19-10.63, <i>P</i><.001) while this ratio was 4.59 (95% CI 2.29-9.23, <i>P</i><.001) for patients who experienced an acute ischemic event.</p><p><strong>Conclusion: </strong>Patients with active cancer carry a significant risk for acute ischemic event development during the course of COVID-19 and such patients may require particular attention in terms of anticoagulation therapy.</p><p><strong>Limitations: </strong>Retrospective design and small sample size.</p><p><strong>Conflict of interest: </strong>None.</p>","PeriodicalId":8016,"journal":{"name":"Annals of Saudi Medicine","volume":"43 1","pages":"1-9"},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/29/0256-4947.2023.1.PMC9899339.pdf","citationCount":"0","resultStr":"{\"title\":\"Factors associated with development of an acute ischemic event during hospitalization for COVID-19 in cancer and non-cancer patients.\",\"authors\":\"Arif Hakan Onder, Aysegul Seremet Keskin, Kubra Demir Onder, Filiz Kizilates, Cihan Heybeli\",\"doi\":\"10.5144/0256-4947.2023.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>COVID-19 and solid cancer are both associated with an increased risk of thromboembolism.</p><p><strong>Objectives: </strong>Assess whether solid cancer is a risk factor for acute ischemic event development among patients with COVID-19.</p><p><strong>Design: </strong>Retrospective cohort SETTING: A tertiary training and research hospital PATIENTS AND METHODS: Patients who were hospitalized for COVID-19 for ≥3 days between 15 March 2020 and 30 March 2021 at Antalya Training and Research Hospital, Antalya, Turkiye. were included in the study. Independent predictors of the development of acute ischemic events during hospitalization were determined using multivariable logistic regression analysis.</p><p><strong>Main outcome measures: </strong>Risk factors for acute ischemic event development.</p><p><strong>Sample size: </strong>538 patients.</p><p><strong>Results: </strong>Patients diagnosed with solid cancer comprised 11.3% of the cohort (n=61). Forty-one (7.6%) developed an acute ischemic event at a median of 3 (range, 1-15) days after hospitalization. The presence of a solid cancer (OR 3.80, 95% CI 1.20-12.03, <i>P</i>=.023) along with length of hospital stay (OR 1.05 per day, 95% CI 1.01-1.09, <i>P</i>=.025) were independent predictors of acute ischemic event development during the course of COVID-19. Mortality was reported in 200 (37%) patients at a median of 5 (range, 3-10) days after hospitalization. The presence of solid tumor increased mortality 5.83 times (95% CI 3.19-10.63, <i>P</i><.001) while this ratio was 4.59 (95% CI 2.29-9.23, <i>P</i><.001) for patients who experienced an acute ischemic event.</p><p><strong>Conclusion: </strong>Patients with active cancer carry a significant risk for acute ischemic event development during the course of COVID-19 and such patients may require particular attention in terms of anticoagulation therapy.</p><p><strong>Limitations: </strong>Retrospective design and small sample size.</p><p><strong>Conflict of interest: </strong>None.</p>\",\"PeriodicalId\":8016,\"journal\":{\"name\":\"Annals of Saudi Medicine\",\"volume\":\"43 1\",\"pages\":\"1-9\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/29/0256-4947.2023.1.PMC9899339.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Saudi Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5144/0256-4947.2023.1\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Saudi Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5144/0256-4947.2023.1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:COVID-19和实体癌都与血栓栓塞风险增加相关。目的:评估实体癌是否是COVID-19患者急性缺血性事件发展的危险因素。设计:回顾性队列设置:三级培训和研究医院患者和方法:2020年3月15日至2021年3月30日期间在土耳其安塔利亚培训和研究医院因COVID-19住院≥3天的患者。都被纳入了研究。使用多变量logistic回归分析确定住院期间急性缺血性事件发展的独立预测因子。主要观察指标:急性缺血性事件发展的危险因素。样本量:538例患者。结果:确诊为实体癌的患者占队列的11.3% (n=61)。41例(7.6%)在住院后中位数3天(范围1-15天)发生急性缺血事件。实体癌的存在(OR 3.80, 95% CI 1.20-12.03, P= 0.023)和住院时间(OR 1.05 /天，95% CI 1.01-1.09, P= 0.025)是COVID-19期间急性缺血性事件发展的独立预测因子。200例(37%)患者在住院后中位数5天(范围3-10天)死亡。实体瘤的存在使死亡率增加5.83倍(95% CI 3.19-10.63, ppp)。结论:活动性癌症患者在COVID-19病程中急性缺血性事件发展的风险显著，此类患者在抗凝治疗方面需要特别注意。局限性:回顾性设计和小样本量。利益冲突:无。
Factors associated with development of an acute ischemic event during hospitalization for COVID-19 in cancer and non-cancer patients.
Background: COVID-19 and solid cancer are both associated with an increased risk of thromboembolism.
Objectives: Assess whether solid cancer is a risk factor for acute ischemic event development among patients with COVID-19.
Design: Retrospective cohort SETTING: A tertiary training and research hospital PATIENTS AND METHODS: Patients who were hospitalized for COVID-19 for ≥3 days between 15 March 2020 and 30 March 2021 at Antalya Training and Research Hospital, Antalya, Turkiye. were included in the study. Independent predictors of the development of acute ischemic events during hospitalization were determined using multivariable logistic regression analysis.
Main outcome measures: Risk factors for acute ischemic event development.
Sample size: 538 patients.
Results: Patients diagnosed with solid cancer comprised 11.3% of the cohort (n=61). Forty-one (7.6%) developed an acute ischemic event at a median of 3 (range, 1-15) days after hospitalization. The presence of a solid cancer (OR 3.80, 95% CI 1.20-12.03, P=.023) along with length of hospital stay (OR 1.05 per day, 95% CI 1.01-1.09, P=.025) were independent predictors of acute ischemic event development during the course of COVID-19. Mortality was reported in 200 (37%) patients at a median of 5 (range, 3-10) days after hospitalization. The presence of solid tumor increased mortality 5.83 times (95% CI 3.19-10.63, P<.001) while this ratio was 4.59 (95% CI 2.29-9.23, P<.001) for patients who experienced an acute ischemic event.
Conclusion: Patients with active cancer carry a significant risk for acute ischemic event development during the course of COVID-19 and such patients may require particular attention in terms of anticoagulation therapy.
Limitations: Retrospective design and small sample size.
期刊介绍：
The Annals of Saudi Medicine (ASM) is published bimonthly by King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. We publish scientific reports of clinical interest in English. All submissions are subject to peer review by the editorial board and by reviewers in appropriate specialties. The journal will consider for publication manuscripts from any part of the world, but particularly reports that would be of interest to readers in the Middle East or other parts of Asia and Africa. Please go to the Author Resource Center for additional information.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
